Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;54(2):469–477. doi: 10.4143/crt.2021.205

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Survival outcomes. (A) Overall survival from the start of preceding regimen. (B) Progression-free survival_C+E, composite progression-free survival from the start of preceding regimen to the event of the following regimen between CDK4/6i or EVE-based regimens. (C) Progression-free survival_C, progression-free survival for CDK4/6i-based regimen. (D) Progression-free survival_E, progression-free survival for EVE-based regimen. (E) Progression-free survival₁, progression-free survival for the preceding regimen and (F) progression-free survival₂, progression-free survival for the following regimen between CDK4/6i- and EVE-based regimens. C or CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; E or EVE, everolimus; NE, not estimated.